DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer

Epigenetics

Volumn 10, Issue 8, 2015, Pages 736-748

  Zhang, Wa ^a   Barger, Carter J ^a   Link, Petra A ^b   Mhawech Fauceglia, Paulette ^b,c   Miller, Austin ^b   Akers, Stacey N ^b   Odunsi, Kunle ^b   Karpf, Adam R ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cancer germline genes; Cancer testis antigen genes; CT45; Decitabine; DNA methylation; Epithelial ovarian cancer

Indexed keywords

CANCER TESTIS ANTIGEN; CANCER TESTIS ANTIGEN 45; DECITABINE; UNCLASSIFIED DRUG; AZACITIDINE; CT45A1 PROTEIN, HUMAN; MESSENGER RNA; TUMOR ANTIGEN;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; OVARY CARCINOMA; OVERALL SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; AGED; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; DISEASE COURSE; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

AGED; ANTIGENS, NEOPLASM; AZACITIDINE; CELL LINE, TUMOR; DISEASE PROGRESSION; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER;

EID: 84943749335     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.1080/15592294.2015.1062206     Document Type: Article

References (46)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer J Int du Cancer 2010; 127: 2893-917; PMID: 21351269; http://dx. doi. org/10. 1002/ijc. 25516.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29; PMID: 25559415.
3. Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014; 124: 1-5; PMID: 24219974; http://dx. doi. org/10. 1016/j. ijgo. 2013. 10. 001.
4. Roett MA, Evans P. Ovarian cancer: an overview. Am Fam Physician 2009; 80: 609-16; PMID: 19817326.
5. Romero I, Bast RC, Jr. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology 2012; 153: 1593-602; PMID: 22416079; http://dx. doi. org/10. 1210/en. 2011-2123.
6. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 615-25; PMID: 16034368; http://dx. doi. org/10. 1038/nrc1669.
7. Akers SN, Odunsi K, Karpf AR. Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol (London, England) 2010; 6: 717-32; PMID: 20465387; http://dx. doi. org/10. 2217/fon. 10. 36.
8. Woloszynska-Read A, Mhawech-Fauceglia P, Yu J, Odunsi K, Karpf AR. Intertumor and intratumor NYESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. Clin Cancer Res 2008; 14: 3283-90; PMID: 18519754; http://dx. doi. org/10. 1158/1078-0432. CCR-07-5279.
9. James SR, Link PA, Karpf AR. Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b. Oncogene 2006; 25: 6975-85; PMID: 16715135; http://dx. doi. org/10. 1038/sj. onc. 1209678.
10. De Smet C, De Backer O, Faraoni I, Lurquin C, Brasseur F, Boon T. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A 1996; 93: 7149-53; PMID: 8692960; http://dx. doi. org/10. 1073/pnas. 93. 14. 7149.
11. James SR, Cedeno CD, Sharma A, Zhang W, Mohler JL, Odunsi K, Wilson EM, Karpf AR. DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11. Epigenetics 2013; 8: 849-63; PMID: 23839233; http://dx. doi. org/10. 4161/epi. 25500.
12. De Smet C, Lurquin C, Lethe B, Martelange V, Boon T. DNA methylation is the primary silencing mechanism for a set of germ line-and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 1999; 19: 7327-35; PMID: 10523621.
13. Cannuyer J, Loriot A, Parvizi GK, De Smet C. Epigenetic hierarchy within the MAGEA1 cancer-germline gene: promoter DNA methylation dictates local histone modifications. PloS one 2013; 8: e58743; PMID: 23472218; http://dx. doi. org/10. 1371/journal. pone. 0058743.
14. Chen YT, Scanlan MJ, Venditti CA, Chua R, Theiler G, Stevenson BJ, Iseli C, Gure AO, Vasicek T, Strausberg RL, et al. Identification of cancer/testis-antigen genes by massively parallel signature sequencing. Proc Natl Acad Sci U S A 2005; 102: 7940-5; PMID: 15905330; http://dx. doi. org/10. 1073/pnas. 0502583102.
15. Rudolph P, Kellner U, Schmidt D, Kirchner V, Talerman A, Harms D, Parwaresch R. Ki-A10, a germ cell nuclear antigen retained in a subset of germ cell-derived tumors. Am J Pathol 1999; 154: 795-803; PMID: 10079257; http://dx. doi. org/10. 1016/S0002-9440(10)65326-6.
16. Heidebrecht HJ, Claviez A, Kruse ML, Pollmann M, Buck F, Harder S, Tiemann M, Dorffel W, Parwaresch R. Characterization and expression of CT45 in Hodgkin's lymphoma. Clin Cancer Res 2006; 12: 4804-11; PMID: 16914565; http://dx. doi. org/10. 1158/1078-0432. CCR-06-0186.
17. Chen YT, Hsu M, Lee P, Shin SJ, Mhawech-Fauceglia P, Odunsi K, Altorki NK, Song CJ, Jin BQ, Simpson AJ, et al. Cancer/testis antigen CT45: analysis of mRNA and protein expression in human cancer. Int J Cancer J Int du Cancer 2009; 124: 2893-8; PMID: 19296537; http://dx. doi. org/10. 1002/ijc. 24296.
18. Chen YT, Ross DS, Chiu R, Zhou XK, Chen YY, Lee P, Hoda SA, Simpson AJ, Old LJ, Caballero O, et al. Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PloS one 2011; 6: e17876; PMID: 21437249; http://dx. doi. org/10. 1371/journal. pone. 0017876.
19. Andrade VC, Vettore AL, Regis Silva MR, Felix RS, Almeida MS, de Carvalho F, Zago MA, Caballero OL, Simpson AJ, Colleoni GW. Frequency and prognostic relevance of cancer testis antigen 45 expression in multiple myeloma. Experimental hematology 2009; 37: 446-9; PMID: 19211183; http://dx. doi. org/10. 1016/j. exphem. 2008. 12. 003.
20. Claviez A, Mauz-Körholz C, Heidebrecht H-J, Schellong G, Körholz D, Dörffel W, Parwaresch R, Tiemann M. Cancer/testis antigen CT45 is frequently expressed in Hodgkin's lymphoma and associated with nodular sclerosis subtype and advanced disease; meeting abstract. Blood 2006; 108: 4591.
21. Claviez A., H. J. H, W. D, R. P, M. T. CT45 expression in pediatric Hodgkin's lymphoma is associated with nodular sclerosis subtpe, presence of B symptoms and advanced disease stages.; meeting abstract. Haematologica 2007; 92: 62; http://dx. doi. org/10. 3324/haematol. 11440.
22. Chen YT, Chadburn A, Lee P, Hsu M, Ritter E, Chiu A, Gnjatic S, Pfreundschuh M, Knowles DM, Old LJ. Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas. Proc Natl Acad Sci U S A 2010; 107: 3093-8; PMID: 20133697; http://dx. doi. org/10. 1073/pnas. 0915050107.
23. Koop A, Sellami N, Adam-Klages S, Lettau M, Kabelitz D, Janssen O, Heidebrecht HJ. Down-regulation of the cancer/testis antigen 45 (CT45) is associated with altered tumor cell morphology, adhesion and migration. Cell Commun Signal 2013; 11: 41; PMID: 23758873; http://dx. doi. org/10. 1186/1478-811X-11-41.
24. Shang B, Gao A, Pan Y, Zhang G, Tu J, Zhou Y, Yang P, Cao Z, Wei Q, Ding Y, et al. CT45A1 acts as a new proto-oncogene to trigger tumorigenesis and cancer metastasis. Cell death & disease 2014; 5: e1285; PMID: 24901056; http://dx. doi. org/10. 1038/cddis. 2014. 244.
25. Karpf AR, Jones DA. Reactivating the expression of methylation silenced genes in human cancer. Oncogene 2002; 21: 5496-503; PMID: 12154410; http://dx. doi. org/10. 1038/sj. onc. 1205602.
26. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-15; PMID: 21720365; http://dx. doi. org/10. 1038/nature10166.
27. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev 2011; 25: 1010-22; PMID: 21576262; http://dx. doi. org/10. 1101/gad. 2037511.
28. Liu X, Gorovsky MA. Mapping the 5' and 3' ends of Tetrahymena thermophila mRNAs using RNA ligase mediated amplification of cDNA ends (RLM-RACE). Nucleic acids Res 1993; 21: 4954-60; PMID: 8177745; http://dx. doi. org/10. 1093/nar/21. 21. 4954.
29. Maruyama K, Sugano S. Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides. Gene 1994; 138: 171-4; PMID: 8125298; http://dx. doi. org/10. 1016/0378-1119(94)90802-8.
30. Smale ST. Transcription initiation from TATA-less promoters within eukaryotic protein-coding genes. Biochimica et biophysica acta 1997; 1351: 73-88; PMID: 9116046; http://dx. doi. org/10. 1016/S0167-4781(96)00206-0.
31. Cerveira N, Meyer C, Santos J, Torres L, Lisboa S, Pinheiro M, Bizarro S, Correia C, Norton L, Marschalek R, et al. A novel spliced fusion of MLL with CT45A2 in a pediatric biphenotypic acute leukemia. BMC Cancer 2010; 10: 518; PMID: 20920256; http://dx. doi. org/10. 1186/1471-2407-10-518.
32. Woloszynska-Read A, Zhang W, Yu J, Link PA, Mhawech-Fauceglia P, Collamat G, Akers SN, Ostler KR, Godley LA, Odunsi K, et al. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res 2011; 17: 2170-80; PMID: 21296871; http://dx. doi. org/10. 1158/1078-0432. CCR-10-2315.
33. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429: 457-63; PMID: 15164071; http://dx. doi. org/10. 1038/nature02625.
34. Klug M, Rehli M. Functional analysis of promoter CpG methylation using a CpG-free luciferase reporter vector. Epigenetics 2006; 1: 127-30; PMID: 17965610; http://dx. doi. org/10. 4161/epi. 1. 3. 3327.
35. Whitehurst AW. Cause and consequence of cancer/testis antigen activation in cancer. Ann Rev Pharmacol Toxicol 2014; 54: 251-72; PMID: 24160706; http://dx. doi. org/10. 1146/annurev-pharmtox-011112-140326.
36. Odunsi K, Sabbatini P. Harnessing the immune system for ovarian cancer therapy. Am J Reproduct Immunol 2008; 59: 62-74; PMID: 18154597; http://dx. doi. org/10. 1111/j. 1600-0897. 2007. 00560. x.
37. Odunsi K, Matsuzaki J, James SR, Mhawech-Fauceglia P, Tsuji T, Miller A, Zhang W, Akers SN, Griffiths EA, Miliotto A, et al. Epigenetic potentiation of NYESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res 2014; 2: 37-49; PMID: 24535937; http://dx. doi. org/10. 1158/2326-6066. CIR-13-0126.
38. Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, et al. Ipilimumab for patients with advanced mucosal melanoma. The oncologist 2013; 18: 726-32; PMID: 23716015; http://dx. doi. org/10. 1634/theoncologist. 2012-0464.
39. Srivastava P, Paluch BE, Matsuzaki J, James SR, Collamat-Lai G, Taverna P, Karpf AR, Griffiths EA. Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics 2015; 10: 237-46; PMID: 25793777.
40. Karpf AR. A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy. Epigenetics 2006; 1: 116-20; PMID: 17786175; http://dx. doi. org/10. 4161/epi. 1. 3. 2988.
41. Akers SN, Moysich K, Zhang W, Collamat Lai G, Miller A, Lele S, Odunsi K, Karpf AR. LINE1 and Alu repetitive element DNA methylation in tumors and white blood cells from epithelial ovarian cancer patients. Gynecol Oncol 2014; 132: 462-7; PMID: 24374023; http://dx. doi. org/10. 1016/j. ygyno. 2013. 12. 024.
42. Woloszynska-Read A, James SR, Link PA, Yu J, Odunsi K, Karpf AR. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun 2007; 7: 21; PMID: 18095639.
43. Yuan Y, Kim WH, Han HS, Lee JH, Park HS, Chung JK, Kang SB, Park JG. Establishment and characterization of human ovarian carcinoma cell lines. Gynecol Oncol 1997; 66: 378-87; PMID: 9299249; http://dx. doi. org/10. 1006/gyno. 1997. 4785.
44. Yanagibashi T, Gorai I, Nakazawa T, Miyagi E, Hirahara F, Kitamura H, Minaguchi H. Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20. Br J Cancer 1997; 76: 829-35; PMID: 9328139; http://dx. doi. org/10. 1038/bjc. 1997. 471.
45. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1; PMID: 23550210; http://dx. doi. org/10. 1126/scisignal. 2004088.
46. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Dis 2012; 2: 401-4; PMID: 22588877; http://dx. doi. org/10. 1158/2159-8290. CD-12-0095.